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Introduction

Vitamin D derangements are a rare but important cause of hypercalcemia. Granulomatous
disease is a primary cause of vitamin D derangements and is frequently associated with
sarcoidosis, tuberculosis, and in the present case, foreign body granulomatosis. Liquid or
injectable silicone is used as a filler for cosmetic body contouring. Transgender patients may
seek silicone injections as part of gender affirmation surgeries. Granuloma formation is a
rare but well-described complication of injectable silicone.
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Case Description

A 40-year-old, assigned male at birth (AMAB) transgender female patient, with a history of
HIV and chronic kidney disease (CKD) stage 3b, was admitted to the emergency department
for evaluation of hypercalcemia. One year prior, the hypercalcemia was attributed to CKD
secondary to HIV or HIV medications. The patient presented after two weeks of polyuria
and polydipsia. Her vital signs were stable, and the physical exam, EKG, and chest x-ray were
unremarkable. Labs were notable for calcium (14.1 mg/dL, assay normal range 8.5-10.5 mg/
dL) and acute-on-chronic kidney disease. Follow-up labs were consistent with a vitamin D
aberration causing hypercalcemia, raising suspicion for granulomatous disease. CT chest/abdomen/pelvis without contrast demonstrated diffuse skin thickening of the bilateral breasts
and buttocks with associated ill-defined soft tissue density and scattered punctate calcifications. No hilar adenopathy or lung abnormalities were observed, decreasing the suspicion
of sarcoidosis or an infectious etiology. The patient disclosed having received free silicone
injections to which the hypercalcemia was attributed. After single doses of calcitonin (100U
SC/IM) and zoledronic acid (4 mg IV), her hypercalcemia resolved. Kidney function gradually
returned to baseline with IV fluids.

Conclusion

This case illustrates the importance of readily recognizing the imaging characteristics of free
silicone granulomatosis, which showed subcutaneous fat infiltrated with soft tissue nodules
and calcifications. The distribution of findings in the bilateral breast and buttocks and history of free silicone injections were most useful in arriving at a diagnosis and treatment plan.
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Introduction

Hypercalcemia is a commonly encountered
disorder that can result from multiple etiologies and cause significant morbidity and mortality if not properly evaluated and treated.1,2
Clinical manifestations of hypercalcemia can

vary and are usually present with a calcium level
of greater than 12 mg/dL. Hypercalcemia can
be mild (10.5 to 11.9 mg/dL), moderate (12 to
13.9 mg/dL), or a hypercalcemic crisis (14.0 to
16.0 mg/dL). The most common symptoms of
hypercalcemia include abdominal pain, nausea/
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vomiting, bone pain, fatigue, constipation,
lethargy, and/or altered mental status. Hypercalcemia can also present with nephrolithiasis,
pancreatitis, and/or cardiac arrhythmias.1 Vitamin D derangements are a less common but
important cause of hypercalcemia. Granulomatous disease is the main perpetrator in vitamin
D derangements and is a hallmark of sarcoidosis, tuberculosis, or, as we will describe in the
case below, foreign body granulomatosis.1,2
Vitamin D (1,25 dihydroxyvitamin D) is a steroid
hormone responsible for increasing the absorption of calcium and phosphate, primarily from
the gut.2,3 Inactive vitamin D is normally converted to its active form by 1-alpha-hydroxylase
found in renal tubular cells, but the enzyme is
also found in macrophages. Renal cells have a
well-established negative feedback mechanism
to lower 1-alpha-hydroxylase (CYP27B1) production when 1,25 dihydroxyvitamin D is high.
Vitamin D regulatory mechanisms are limited
in macrophages, leading to abnormally elevated vitamin D levels in granulomatous disease
caused by foreign bodies, sarcoidosis, or tuberculosis.2,3
Liquid or injectable silicone is a non-biodegradable, inert material used as an injectable
filler for cosmetic body contouring. Granuloma
formation is a rare but well-described complication of injectable silicone.4,5 Injectable silicone
is not FDA-approved for aesthetic procedures
of the face or body. Practitioners administering
silicone, in the United States (US) or abroad,
may be unlicensed or unqualified to do so.5
The majority of patients seeking cosmetic procedures such as body contouring are female.
Male-to-female transgender patients are a
small subset who may seek such procedures as
part of gender affirmation. Gender-affirming
therapies have been shown to improve quality
of life and self-esteem. In addition, gender affirming surgeries generally have a high satisfaction rate.6
We present a case in which a patient, assigned
male at birth (AMAB), transgender female, was
admitted for worsening, severe hypercalcemia.
The hypercalcemia was eventually attributed
to granulomatosis from free silicone injections
of the breasts and buttocks performed several
years prior.
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Case Description

A 40-year-old, assigned male at birth, transgender female patient, with a history of human immunodeficiency virus (HIV) and chronic
kidney disease (CKD) stage 3, was admitted
for evaluation of hypercalcemia. Her home
medications included antiretroviral therapy
with rilpivirine and dolutegravir and vitamin D
supplementation. One year prior to the current
ED admission, she had been evaluated as an
outpatient for hypercalcemia. This prior workup
revealed an inappropriately normal parathyroid
hormone (PTH), normal PTH-related protein,
and a low vitamin D level. Her hypercalcemia
at that time was attributed to CKD secondary
to HIV or HIV medications. Two weeks prior to
emergency department (ED) presentation, she
was found to have elevated calcium levels and
discontinued her vitamin D supplementation.
The patient presented to the ED on the recommendation of her nephrologist due to a 2-week
history of polyuria and polydipsia. The outpatient lab work revealed worsening acute-onchronic kidney injury and persistent elevation
of calcium up to 13.6 mg/dL. Upon presentation
to the ED, her vital signs were stable. Physical
exam, EKG, and chest X-ray were unremarkable. Labs were notable for elevated calcium
(14.1 mg/dL, assay normal range 8.5-10.5 mg/
dL) and acute-on-chronic kidney disease with
a blood urea nitrogen (BUN) of 48 mg/dL and
creatinine of 2.75 mg/dL (our patient’s baseline
was 1.6 mg/dL). Follow-up laboratory studies
revealed a low 25-hydroxyvitamin D level (18
ng/mL, assay normal range 30-80 ng/mL),
appropriately low PTH (7 pg/mL, assay normal
range 7.5-53.5 pg/mL), a non-detectable PTHrP,
elevated 1,25-dihydroxyvitamin D level (130 pg/
mL, assay normal range 21-65 pg/mL), and
elevated ionized calcium (7.94 mg/dL, normal
assay range 4.50-5.30 mg/dL). These laboratory
findings were consistent with a vitamin D aberration causing hypercalcemia, raising suspicion
for granulomatous disease such as sarcoidosis.
An angiotensin-converting enzyme (ACE) level
was obtained, which was within normal limits.
Both urine protein electrophoresis (UPEP) and
serum protein electrophoresis (SPEP) were
negative making multiple myeloma less likely.
Further imaging with CT chest/abdomen/pelvis
without contrast was obtained. The CT demonstrated diffuse skin thickening of the bilateral
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Figure 1. An axial CT image at the level of the breasts demonstrating abnormal, diffuse soft tissue
density replacing fatty tissue about the implants with associated scattered calcifications. The
pectoralis muscles were also involved (posterior to the implants).
breasts and buttocks with associated ill-defined soft tissue density and scattered punctate calcifications within the subcutaneous fat,
pectoralis, and gluteus muscles (Figures 1 and
2). Additionally, bilateral breast implants were
noted. No hilar adenopathy or lung abnormalities were observed, decreasing the suspicion
for sarcoidosis or an infectious etiology such as
tuberculosis. However, there was bilateral inguinal and axillary adenopathy with the largest
individual node measuring up to 2 cm (Figure
3).
An ultrasound-guided axillary lymph node
biopsy was performed and showed non-specific reactive lymphadenitis without evidence
of granulomatous disease. Imaging findings
prompted further discussions with the patient
about prior surgeries or procedures. The pa-

tient divulged a history of receiving bilateral
breast and buttock free silicone injections
in Mexico several years prior. This new information helped guide the discussions among
pulmonology and radiology services with the
consensus that the lymphadenopathy and soft
tissue findings were consistent with granulomatosis due to free silicone injection and was
the likely cause of the hypercalcemia.
Overall, the patient’s hospital course was uneventful. She was initially given single doses of
calcitonin (100U SC/IM) and zoledronic acid (4
mg IV) with IV fluids throughout her hospital
stay. The hypercalcemia resolved and her kidney
function returned to baseline. She did not
require any additional medications upon discharge and received a plan for close follow-up
with nephrology on an outpatient basis.

Figure 2. An axial CT image at the level of the gluteus also demonstrating abnormal soft tissue
density replacing fatty tissue over the gluteus muscles with scattered associated calcifications.
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Figure 3. An axial CT image at the level of the pelvis demonstrating enlarged bilateral inguinal
lymph nodes. The lymph node that was biopsied is denoted by the white arrow.

Discussion

Symptomatic hypercalcemia can be the first
manifestation of a serious disease, including malignancy, and it is imperative that it be
worked up. Primary hyperparathyroidism and
malignancy are revealed as the etiology for hypercalcemia in approximately 90% of patients.1,7
Malignant etiologies include carcinomas, leukemias, multiple myeloma, and lymphomas. As
was shown in our case, vitamin D derangement
caused by granulomatous disease is a less common but important cause of hypercalcemia.
Elevated blood calcium levels result from abnormally high levels of active vitamin D. The enzyme 1-alpha-hydroxylase (CYP27B1) converts
25-hydroxyvitamin D (inactive form) to 1,25-dihydroxyvitamin D (active form). It is expressed
in many tissues, but renal expression plays an
important role in vitamin D and calcium homeostasis. Renal production of 1-alpha-hydroxylase enzyme (CYP27B1) has a well-established
negative feedback mechanism, which limits
production in the presence of 1,25-dihydroxyvitamin D(product). Macrophages are a main
cell type involved in the granuloma reaction:
their overexpression of 1-alpha-hydroxylase
(CYP27B1) is the main cause of hypercalcemia
in granulomatous disease. Macrophage production of 1-alpha-hydroxylase (CYP27B1) does
not have the same negative feedback mechanism as renal production and there is continued
1-alpha-hydroxylase (CYP27B1) expression even
when 1,25-dihydroxyvitamin D is abundant. This
leads to abnormally increased levels of 1,25-di-
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hydroxyvitamin D, which in turn, increases
blood calcium levels, primarily by increasing the
absorption of calcium in the gut.3,7,8 Work-up
algorithms typically include evaluation of the
vitamin D abnormalities seen in granulomatous
disease such as sarcoidosis and tuberculosis.1
However, it is important to also include foreign
body granulomatous disease in the differential, particularly in transgender individuals who
underwent large-scale body contouring procedures.
Our case illustrates the importance of readily
recognizing the imaging characteristics of free
silicone granulomatosis. As we observed, the
CT will show infiltration of subcutaneous fat
with soft tissue nodules and associated calcifications. Ultrasound findings vary but are
usually associated with hypoechoic, shadowing
masses that may or may not have an echogenic anterior margin but can sometimes mimic
simple cysts. MRI often shows nodules that
are hypointense on T1-weighted images, and
intermediate intensity on T2-weighted images
less than water.9,10 Although not routinely performed, silicone-sensitive MR sequences have
been described in breast MR to aid in detecting
silicone implant rupture. These MR sequences
null fat and suppress water signal intensity,
causing silicone to appear bright against the
dark breast tissue.11 PET/CT appearance of
free-silicone granulomatosis has also been
described as low-level hypermetabolic activity
associated with the above CT findings. However, PET/CT is non-specific and can sometimes
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present a diagnostic dilemma in a patient with
cancer or when an infection is suspected. Other
nuclear medicine exams such as gallium-67 or
MDP-Tc-99 bone scan can also show non-specific soft tissue uptake.12 In the present case,
the most helpful clues for the radiologist were
the distribution of findings in the bilateral
breast and buttocks as well as clinical history of
prior free silicone injections.
Free silicone injections were banned by the
FDA in 1992 and there is ongoing work to
assess their safety. The ban was lifted in 2006
for ophthalmic use only. Free silicone is not
FDA-approved as a dermal cosmetic filler, even
on a small scale.5 Serious associated complications such as cellulitis, necrosis, pneumonitis,
systemic sclerosis, and embolization have been
described. Granuloma formation is another
known complication of free silicone injection.
The risk of granuloma formation increases with
the use of free silicone in large volumes, intramuscular injection, and the use of non-medical
grade silicone, all 3 of which likely occurred in
our patient.3 Despite the lack of FDA approval,
body contouring with free silicone still occurs
both in the US and abroad. There are many
published examples of free silicone injection
granulomatosis and hypercalcemia, the majority of them occurring in female patients.13,14
There are a few case reports of similar complications in transgender females.15 Our case was
unique in that the history of prior free silicone
injection was initially withheld, leading to
delayed diagnosis and potentially unnecessary
diagnostic workup including biopsy.

Conclusion

The transgender community is a small but
growing population. Historically, transgender
patients have experienced unequal treatment
resulting in a greater burden of health disparities and outcomes.16 Transgender patients may
lack access and resources to gender-affirming care from licensed and qualified medical
professionals. They may also be reluctant to
divulge details about prior surgeries or treatments that might directly affect their health.
Their reluctance may be due to prior negative
clinical experiences from implicit or explicit
bias, judgment, and/or discrimination from
the healthcare system. Clinicians must take a
thorough history from patients who are trans-

gender as it relates to prior gender-affirming
treatments. It is important to create a safe
and non-judgmental environment for these
patients to freely discuss their medical history
and ongoing needs.
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